News

Public · Published

Cantor Fitzgerald maintains Eli Lilly at Overweight, raises price target to $1600 from $1440

Cantor Fitzgerald kept its Overweight rating on Eli Lilly and raised its price target to $1600 from $1440, an 11.1% increase. The new target was 12.9% above the stock's October 30 closing price of $1417.54.

Published:

Updated:

What happened

Cantor Fitzgerald kept its Overweight rating on Eli Lilly and raised its price target to $1600 from $1440, an 11.1% increase. The new target was 12.9% above the stock’s October 30 closing price of $1417.54.

Confirmed

Global impact / market context

A higher price target signals that Cantor Fitzgerald sees more potential value in Eli Lilly shares, but it is an analyst estimate rather than a company result or guarantee. If investors act on it, buying could support the share price; the article reports no market reaction.

Analyst inference

The five most recent analyst notes in the article set targets between $1596 and $1650, placing Cantor Fitzgerald’s $1600 target near the low end of that range. This shows its revised estimate is broadly within the reported analyst range, not an outlier.

Confirmed

What to watch

  1. Compare future analyst targets with company results and guidance; those measures can show whether expectations for Eli Lilly’s sales and earnings are being met. Analyst inference
  2. Watch for additional rating or target changes in the article’s stated analyst group; further revisions could shift investor expectations for the shares. Analyst inference
  3. The reported $1600 target is an analyst estimate, not a promised share price; the article gives no company forecast or explanation for the revision. Confirmed

Evidence

  • Original source link unavailable